Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
24 February 2018

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Lupin Ltd (Pharmaceuticals - Indian - Bulk Drugs)

Last Price 807.50
Net Changes 7.45
Volume 1754473
Prev Close 800.05
807.50 7.45 (0.93%)
Date: Feb 23,2018 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs


Chart

Stock Price Details

Market Statistics

Open Price 804 Div Yield (%) 0.93
Buy (Size) 0.00(×0) Eps(Rs) 35.42
Sell (Size) 0.00(×0) Book Value(Rs) 335.420239
Buy Quantity 0 Market Cap(Rs.Cr) 36487.82
Sell Quantity 0 Face Value(Rs) 2
Today's High 814 Market Lot 1
Today's Low 803.7 AGM Date Aug
52-Week High 1498.4 Book Closure Date Jul/Aug
52-Week Low 782.1 ISIN No. INE326A01037

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 1286394 0.28
Indian (Promoter & Group) 211243336 46.73
Total of Promoter 212529730 47.02
Non Promoter (Institution) 170120170 37.63
Non Promoter (Non-Institution) 69377642 15.35
Total Non Promoter 239497812 52.98
Total Promoter & Non Promoter 452027542 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 452027542 100.00

Company News

22-Feb-2018  Lupin Ltd - Announcement under Regulation 30 (LODR)-Allotment
Lupin Ltd - Announcement under Regulation 30 (LODR)-Allotment

Disclosure pursuant to the Regulation 30(2) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 - Allotment of shares under ESOP --------------------------------------------------------------------------------------------------------------
21-Feb-2018  Lupin receives final approval for Oseltamivir Phosphate for Or...
Lupin receives final approval for Oseltamivir Phosphate for Oral Suspension

Lupin announced that it has received final approval for its Oseltamivir Phosphate for Oral Suspension from the United States Food and Drug Administration (FDA) to market the generic version of Hoffman-La Roche, Inc.'s Tamiflu for Oral Suspension, 6 mg/mL. Lupin shall commence promoting the product shortly.

Lupin's Oseltamivir Phosphate for Oral Suspension, 6 mg (base)/mL is AB rated generic equivalent of Hoffman- La Roche, Inc's Tamiflu® for Oral Suspension, 6 mg (base)/mL. Oseltamivir Phosphate for Oral Suspension, 6 mg (base)/mL is indicated for i) treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours and ii) prophylaxis of influenza A and B in patients 1 year and older.

Oseltamivir Phosphate for Oral Suspension, 6 mg (base)/mL had annual sales of approximately USD 358 million in the US (IQVIA MAT October 2017).

21-Feb-2018  Lupin launches Memantine Hydrochloride Extended-Release Capsules
Lupin launches Memantine Hydrochloride Extended-Release Capsules

Lupin announced the launch of its Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, 28mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Memantine Hydrochloride ER capsules 7mg, 14mg, 21mg, 28mg are the generic equivalents of Allergan's Namenda XR1' capsules. It is indicated for the treatment of moderate to severe dementia of the Alzheimer's type.

Memantine Hydrochloride ER capsules 7mg, 14mg, 21mg, 28mg had annual sales of approximately USD 936 million in the US (IQVIA MAT December 2017).

21-Feb-2018  Other announcement of Lupin Ltd
Other announcement of Lupin Ltd

Lupin launches generic Namenda XRr capsules in the US.
21-Feb-2018  Lupin Limited - Press Release
Lupin Limited - Press Release

Lupin Limited has informed the Exchange regarding a press release dated February 21, 2018, titled 'Lupin receives FDA approval for generic Tamiflu« for Oral Suspension'.
21-Feb-2018  Lupin Ltd - Announcement under Regulation 30 (LODR)-Press Rele...
Lupin Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin receives FDA approval for generic Tamiflur for Oral Suspension.
21-Feb-2018  Lupin Ltd - Announcement under Regulation 30 (LODR)-Press Rele...
Lupin Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin launches generic Namenda XRr capsules in the US.
21-Feb-2018  Lupin Ltd - Lupin Limited - Press Release
Lupin Ltd - Lupin Limited - Press Release

Lupin Limited - Press Release
12-Feb-2018  Lupin Ltd is up for a third straight session in a row
Lupin Ltd is up for a third straight session in a row

Lupin Ltd is up for a third straight session in a row. The stock is quoting at Rs 838.7, up 2.01% on the day as on 12:54 IST on the NSE. The benchmark NIFTY is up around 0.62% on the day, quoting at 10520. The Sensex is at 34243.09, up 0.7%. Lupin Ltd has dropped around 8.49% in last one month.

Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has dropped around 2.93% in last one month and is currently quoting at 9222.55, up 1.67% on the day. The volume in the stock stood at 8.88 lakh shares today, compared to the daily average of 20.16 lakh shares in last one month.

The benchmark February futures contract for the stock is quoting at Rs 838.75, up 1.9% on the day. Lupin Ltd is down 42.06% in last one year as compared to a 19.48% gain in NIFTY and a 9.87% gain in the Nifty Pharma index.

The PE of the stock is 23.18 based on TTM earnings ending December 17.

12-Feb-2018  Lupin Limited - Press Release
Lupin Limited - Press Release

Lupin Limited has informed the Exchange regarding a press release dated February 12, 2018, titled 'Lupin launches generic Tamiflu. in the US'.
Incorporation Year 1983 
Registered Office Kalpataru Inspire 3rd Floor,Off Western Exp HW Santacruz-E,
,
Maharashtra-400055
Telephone 91-22-6640 2323 
Fax 91-22-6640 8131 
Chairman D B Gupta
Managing Director Nilesh Gupta
Company Secretary R V Satam 
Auditor B S R & Co LLP 
Face Value(Rs)
Market Lot
Listing MSEI,BSE,NSE 
Registrar Lupin Ltd
Kalpataru Inspire,3rd Floor,Santacruz (East),Mumbai - 400 055 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS